Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, Glucagon, Glucose Monitoring, Insulin Delivery Jun 15 | 2020Dapa Reduces Progression to T2DM; Teplizumab Continues to Delay T1DM Onset; Arecor AT247 Faster than Fiasp; ADA Key Press Releases (June 15)Purchase Blast
$599
Posted in: Bolus Insulin Jun 15 | 2020Lilly’s Lyumjev FDA Approved (ultra-rapid lispro)Purchase Blast
$599
Posted in: Glucose Monitoring Jun 15 | 2020Libre 2 US Approval Was Worth the Wait for Abbott, but Not Its Pump PartnersPurchase Blast$599
Posted in: Basal Insulin, Glucagon, Insulin Delivery Jun 14 | 2020Novo QW Insulin Icodec Ph2 Data; Lilly Pump Feasibility Data; New Dasiglucagon Data; January.ai Glucose Prediction Algorithm; Key Press Releases (June 14)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery Jun 13 | 2020Trulicity, Ozempic, Afrezza, Libre, Control IQ, and Onduo RWE at ADA 2020; Sota T2DM CKD Data; vTv Presents TTP399 Ph2 Results; ADA 2020 Key Press Releases (June 13)Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 12 | 2020Medtronic 780G Data Impresses, but CGM Remains a Weak Point; Medtronic ADA 2020 Investor EventPurchase Blast$599
Posted in: Insulin Delivery Jun 12 | 2020Novo Reports Final Sema Obesity Ph3 Topline Data; Jim Malone Joins Bigfoot; ADA 2020 Key Press Releases (June 12)Purchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Jun 12 | 2020Gilead Announces EMA Approval for End-to-End Yescarta CAR-T Manufacturing at Amsterdam FacilityPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T Jun 12 | 2020Thoughts on FDA Refusal-to-File for Ide-cel; bluebird bio Q1 2020 Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 11 | 2020Biocon/Mylan Bs-glargine Approved; Novo to Acquire Corvidia; Lifescan Launches Verio Reflect; Lannett FDA Bs-glargine Meeting; Medtronic 780G CE Mark; Dexcom Launches G6 Pro; ADA ’20 Key Data and Partnership Press Releases (June 11)Purchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring Jun 09 | 2020Tirzepatide CVOT Underway; Dexcom G6 CE Mark for Wear on Upper Arm; Nemaura Medical to Join Russell IndicesPurchase Blast
$599
Posted in: Allogeneic, CAR-T, CD19 Jun 09 | 2020New Pivotal ALLO-501A (ALPHA-2) Trial in DLBCL PostedPurchase Blast
$599
Posted in: Insulin Delivery Jun 05 | 2020Insulet Resumes Omnipod Horizon Pivotal TrialPurchase Blast
$599
Posted in: BCMA, CAR-T Jun 05 | 2020BCMA CAR-T Updates at ASCO 2020 - Ide-cel, Orva-cel, JNJ-4528Purchase Blast
$599
Posted in: Autologous, CAR-T, CD19, CD22 Jun 05 | 2020Autolus Ph1 Alexander Results and ASCO 2020 Investor Call SummaryPurchase Blast
$599
Posted in: GLP-1RA Jun 04 | 2020Semaglutide Ph3 Obesity Positive Topline Results (STEP 1)Purchase Blast
$599
Posted in: BCMA, CAR-T, CD19 Jun 04 | 2020Update on CBMG’s CAR-T Program; Q1 Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Other Jun 03 | 2020Welldoc Insulin Adjustment Program Approved by FDA; Fractyl to Initiate Study for Insulin-dependent T2DM PatientsPurchase Blast
$599
Posted in: Insulin Delivery Jun 03 | 2020Thoughts on Bigfoot's $55M Series C and if Abbott Libre 2 FDA Approval is ImminentPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
